DHR logo

Danaher Corporation Stock Price

NYSE:DHR Community·US$148.7b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 152 Fair Values set on narratives written by author

DHR Share Price Performance

US$0
-211.40 (-100.00%)
US$228.61
Fair Value
US$0
-211.40 (-100.00%)
Price US$0

DHR Community Narratives

·
Fair Value US$228.61 5.6% undervalued intrinsic discount

DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds

0users have liked this narrative
0users have commented on this narrative
70users have followed this narrative
US$228.61
5.6% undervalued intrinsic discount
Revenue
8.04% p.a.
Profit Margin
21.7%
Future PE
28.12x
Price in 2029
US$290.41

Trending Discussion

No trending discussion available.

Updated Narratives

DHR logo

DHR: Bioprocess Recovery And Diagnostics Expansion Will Support Premium Multiple

Fair Value: US$228.61 5.6% undervalued intrinsic discount
70 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Proven track record with mediocre balance sheet.

1 Risk
3 Rewards

Danaher Corporation Key Details

US$25.1b

Revenue

US$10.4b

Cost of Revenue

US$14.8b

Gross Profit

US$10.8b

Other Expenses

US$4.0b

Earnings

Last Reported Earnings
Jun 26, 2026
Next Reporting Earnings
n/a
5.68
58.75%
15.89%
50.5%
View Full Analysis

About DHR

Founded
1969
Employees
59000
CEO
Rainer Blair
WebsiteView website
www.danaher.com

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Recent DHR News & Updates

Seeking Alpha Aug 14

Danaher: 2027 Growth Reacceleration Should Drive Upside

Summary Danaher is rated a Buy, with revenue growth expected to accelerate in 2027 as respiratory headwinds fade and bioprocessing shipments recover. DHR’s valuation is reasonable, trading at a 12% discount to its five-year average P/E, supported by strong recurring revenues and operational excellence. Life Sciences segment shows robust recovery, with 5.5% core growth and margin expansion, driven by improved pharma spending and biotech funding. Bioprocessing order delays are temporary, with over $100 million in revenue shifting to 2027, positioning DHR for future upside. Read the full article on Seeking Alpha

Recent updates

No updates